
    
      Approximately 20 patients were to be enrolled to receive everolimus in an open label manner.
      A total of 9 patients were enrolled to either Stratum 1 or Stratum 2.

      The study was open for enrollment up to 2 years. Because the target enrollment was not
      achieved in this period, study was terminated with less patient than planned.
    
  